Related Experiment Video
Updated: Jul 27, 2026

High Content Screening in Neurodegenerative Diseases
Published on: January 6, 2012
"Holistic" in silico methods to estimate the systemic and CNS bioavailabilities of potential chemotherapeutic agents
1Paratek Pharmaceuticals, Inc, Boston, MA 02111, USA.
Abstract:
A fundamental fact in the drug development process is that physical quantity of chemical substance is needed for experimental determinations. Information that could guide the course of a drug discovery program, in particular the penultimate ADME parameters % oral bioavailability (%F) and CNS permeability (BBB) are not explicitly determined until after large capital, human and time resources have been invested in a particular chemical series to produce the substance. To assure better go/no-go decisions and to protect the risks of a process that necessitates a considerable "front-loading" of resources, project teams are turning to computational methods to estimate these parameters. Herein we provide a detailed review of "holistic" in silico methods toward the estimation of %F and BBB. An unbiased description of the scope and limitations of their installation and application will be given in the context of an on going pharmaceutical project.
More Related Videos
09:41An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
08:47Experimental Quantification of Interactions Between Drug Delivery Systems and Cells In Vitro: A Guide for Preclinical Nanomedicine Evaluation
Published on: September 28, 2022
Related Concept Videos
Bioavailability: Overview
Bioavailability: Overview
Bioavailability Study Design: Single Versus Multiple Dose Studies
Measurement of Bioavailability: Pharmacodynamic Methods
Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems
Modified-Release Drug Delivery Systems: Bioavailability